333 related articles for article (PubMed ID: 29289479)
1. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
Desai AK; Walters CK; Cope HL; Kazi ZB; DeArmey SM; Kishnani PS
Mol Genet Metab; 2018 Feb; 123(2):92-96. PubMed ID: 29289479
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy for infantile-onset Pompe disease.
Chen M; Zhang L; Quan S
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
[TBL] [Abstract][Full Text] [Related]
4. Pompe disease: early diagnosis and early treatment make a difference.
Chien YH; Hwu WL; Lee NC
Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
[TBL] [Abstract][Full Text] [Related]
5. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
Rafael Bretón Martínez J; Martínez AC
J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333
[No Abstract] [Full Text] [Related]
6. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions.
El-Gharbawy AH; Mackey J; DeArmey S; Westby G; Grinnell SG; Malovrh P; Conway R; Kishnani PS
Mol Genet Metab; 2011; 104(1-2):118-22. PubMed ID: 21802969
[TBL] [Abstract][Full Text] [Related]
7. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
8. Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa.
Gragnaniello V; Fecarotta S; Pecoraro A; Tarallo A; Catzola A; Spadaro G; Parenti G; Della Casa R
Neurol Sci; 2019 Jul; 40(7):1453-1455. PubMed ID: 30778879
[TBL] [Abstract][Full Text] [Related]
9. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
[TBL] [Abstract][Full Text] [Related]
10. Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy.
McIntosh PT; Hobson-Webb LD; Kazi ZB; Prater SN; Banugaria SG; Austin S; Wang R; Enterline DS; Frush DP; Kishnani PS
Mol Genet Metab; 2018 Feb; 123(2):85-91. PubMed ID: 29050825
[TBL] [Abstract][Full Text] [Related]
11. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
[TBL] [Abstract][Full Text] [Related]
12. Early higher dosage of alglucosidase alpha in classic Pompe disease.
Spada M; Pagliardini V; Ricci F; Biamino E; Mongini T; Porta F
J Pediatr Endocrinol Metab; 2018 Dec; 31(12):1343-1347. PubMed ID: 30433875
[TBL] [Abstract][Full Text] [Related]
13. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
[TBL] [Abstract][Full Text] [Related]
14. Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study.
Ditters IAM; van der Beek NAME; Brusse E; van der Ploeg AT; van den Hout JMP; Huidekoper HH
Orphanet J Rare Dis; 2023 May; 18(1):108. PubMed ID: 37158969
[TBL] [Abstract][Full Text] [Related]
15. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P
Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291
[TBL] [Abstract][Full Text] [Related]
16. Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions.
Ditters IAM; van Kooten HA; van der Beek NAME; Hardon JF; Ismailova G; Brusse E; Kruijshaar ME; van der Ploeg AT; van den Hout JMP; Huidekoper HH
BioDrugs; 2023 Sep; 37(5):685-698. PubMed ID: 37326923
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
[TBL] [Abstract][Full Text] [Related]
18. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
[TBL] [Abstract][Full Text] [Related]
19. Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry.
Lessard LER; Tard C; Salort-Campana E; Sacconi S; Béhin A; Bassez G; Orlikowski D; Merle P; Nollet S; Gallay L; Bérard F; Robinson P; Bouhour F; Laforêt P
Mol Genet Metab; 2023 Jul; 139(3):107611. PubMed ID: 37285781
[TBL] [Abstract][Full Text] [Related]
20. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
